NanoViricides, Inc. (NNVC)
- Previous Close
1.1750 - Open
1.1900 - Bid 1.0800 x 3000
- Ask 1.4000 x 4000
- Day's Range
1.1000 - 1.1899 - 52 Week Range
1.0000 - 2.0000 - Volume
22,323 - Avg. Volume
36,854 - Market Cap (intraday)
12.957M - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8000 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.50
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
www.nanoviricides.comRecent News: NNVC
Performance Overview: NNVC
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NNVC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NNVC
Valuation Measures
Market Cap
13.84M
Enterprise Value
8.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.11
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.98
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.95%
Return on Equity (ttm)
-57.90%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.36M
Diluted EPS (ttm)
-0.8000
Balance Sheet and Cash Flow
Total Cash (mrq)
5.25M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.67M
Research Analysis: NNVC
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell